ARMS2 and age-related macular degeneration: Kawashima et al. [37], in AMD (n = 15) or PCV (n = 26) patients treated with aflibercept, who had been previously treated with ranibizumab, did not report significant results on the relationship between ARMS2 A69S (rs10490924), CFH I62V (rs800292), or CFH Y402H (rs1061170) genetic variants and visual improvement.